Pr Philippe Moreau
- Specialty
- Hematologist, multiple myeloma expert
- Hospital
- Centre Hospitalier Universitaire de Nantes
- Latest articles
-
- Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. (Feb 24, 2026)
- Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. (Jan 20, 2026)
- Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions. (Jan 13, 2026)
- Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load. (Dec 18, 2025)
- European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma. (Dec 13, 2025)